Quantum-Si Inc

Quantum‑Si’s latest ownership shifts show no operational impact, while its chip‑powered protein sequencing tech keeps pushing proteomics toward new drug discovery breakthroughs.

Quantum‑Si’s 4Q 2025 miss fuels a strategic pivot toward its flagship Proteus platform, backed by $215 M cash, modest revenue outlook, and analyst‑adjusted price targets.

Quantum‑Si’s cutting‑edge semiconductor chip drives single‑molecule protein sequencing, promising breakthroughs in diagnostics and drug discovery despite volatile stock performance.

Quantum‑Si’s new V3 Library Prep Kit boosts single‑molecule protein sequencing, aiming to accelerate drug discovery—yet the company remains unprofitable amid Nasdaq volatility.

Quantum‑Si Inc. offers a semiconductor‑based single‑molecule protein sequencing platform poised to transform drug discovery, but its volatile stock and negative earnings underscore the challenges of turning cutting‑edge tech into profit.

Quantum-Si Incorporated is revolutionizing the health care sector with its innovative semiconductor chip technology, enabling single-molecule protein sequencing and poised to transform drug discovery and diagnostics.

Quantum-Si Inc. has reported its latest quarterly earnings, with a stock price of $1.20 and a market capitalization of $212.45 million, despite a complex valuation landscape due to the company’s lack of profits.